Patient centricity in action: Medical affairs as a catalyst for transformation

Growing consumerism. Regulatory requirements. Greater recognition of diverse patient needs. More competition and advances in data availability, analytics and technology. All of these reasons and more have pushed the pharmaceutical industry to increase its focus on patient centricity in the past decade. And while a diverse set of stakeholders have given it significant attention, many companies still struggle to clearly define it and establish best practices for creating meaningful impact for patients and businesses.

ZS defines patient centricity as an organizational culture and set of business practices that consistently place patients at the heart of decision-making and respond to their needs—as articulated by the patients themselves—while driving positive business outcomes. Medical affairs teams can play a major role in advancing patient centricity.

This white paper explores how medical affairs can leverage its unique position within pharmaceutical organizations to drive practice change, improve patient outcomes and address gaps in patient engagement and access to medicines

Download the paper to learn:

• The current state of patient centricity and medical affairs engagement strategies
• What direct and indirect medical impact looks like across the product life cycle
• How an internal transformation toward patient centricity can drive external impact
• How medical affairs can successfully manage the transition to a patient-centric organization

Download the white paper